Synthesis and atypical antipsychotic profile of some 2-(2-piperidinoethyl)benzocycloalkanones as analogues of butyrophenone by Fontenla, José Ángel et al.
2564 J .  Med. Chem. 1994,37, 2564-2573 
Synthesis and Atypical Antipsychotic Profile of Some 
2-(2-Piperidinoethyl)benzocycloalkanones as Analogues of Butyrophenonet 
Jose A. Fontenla,*$* Javier Osuna,* Elizabeth Rosa,* Ma Elena Castro,* Tom& G-Ferreiro,* Isabel Loza-Garcia,S 
Jose M. Calleja,* F e r r h  Sanz,g Jesds Rodriguez,* Enrique Ravifia,l Javier Fueyo,l Christian F-Masaguer,l 
Antonio Vidal,l and Maria L. de Ceballosll 
Department of Pharmacology, Faculty of Pharmacy, and Department of Organic Chemistry, Laboratory of Pharmaceutical 
Chemistry, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain, Department of Medical Informatics, 
Znstitut Municipal d‘lnvestigacw Mhdica (UAB), c lDoctor Aiguader, 80, 08003 Barcelona, Spain, and Department of 
Neuropharmacology, Cajal Institute, CSIC, 28002 Madrid, Spain 
Received January 27, 1994@ 
Four new 2-(2-piperidinoethyl)benzocycloalkanone derivatives, 20-23, were prepared and 
evaluated as potential antipsychotic agents in receptor binding assays for dopamine (DA) and 
5-HTu receptors and in functional and behavioral screens. Their affinities for D2 receptors 
(Ki’s in the nanomolar range: 46.7-70.7) and D1 receptors (Ki’s in the micromolar range: 1.09- 
2.81) were slightly lower than that showed by haloperidol (Ki’s in the nanomolar range: 5.01 
and 97.72 for D2 and for D1 receptors, respectively). The ratio of pKi’s values D1/D2 showed 
that the new molecules are more Dz-selective than haloperidol. In contrast, in the L3H1- 
ketanserin binding assays the new compounds had greater affinity for 5-HTu receptors (pKi’s 
7.89-8.60) than haloperidol (pKi 7.70) and in functional studies, endothelium-stripped aorta 
rings, the p A 2  values (6.75-8.12) were slightly lower than that of ketanserin (8.87) in suppresing 
serotonin-induced contractions. The pKi’s for D2 binding (and to a lesser extent pKi’s for D1 
binding) tend to be greater among typical (classical) than among atypical antipsychotics, while 
these two classes of antipsychotics exhibit no difference with regard to  pKi’s for 5-HTu receptors. 
The ratios of pK;s for 5-HTzpJD2 receptors may be useful for rapid screening of new compounds, 
and its potential induction of extrapyramidal symptoms (ratio values > 1.12 were predictive of 
an atypical antipsychotic profile). The new molecules had a ratio value in the range 1.08- 
1.20, while haloperidol showed a ratio of 0.93. In the behavioral screening tests, the new 
molecules showed antagonist activity of amphetamine-inducing hyperactivity and apomorphine- 
induced climbing (predictive tests for antipsychotic activity). In the catalepsy test (predictive 
test for induction of extrapyramidal symptoms), the values obtained were in accordance with 
an atypical antipsychotic drugs profile. 
Introduction 
Administration of neuroleptics such as chlorpro- 
mazine or haloperidol is still the only effective treatment 
of a variety of psychiatric disorders (schizophrenia, the 
manic phase of manic-depressive psychosis). However, 
most neuroleptics (also called “classical antipsychotics”) 
have two major drawbacks. First, they can induce 
extrapyramidal symptoms (sometimes at the start of 
treatment or following monthdyears of therapy). Sec- 
ond, negative symptoms (such as blunted affectivity, 
emotional withdrawal, apathy, and motor retardation) 
respond poorly in most patients. Since the 1970s, 
atypical (nonclassical) antipsychotics which have no 
extrapyramidal side effects and are effective against 
negative symptoms have been available. The prototype 
of this group, clozapine, whose atypical activity has been 
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attributed classically to its anticholinergic activity, was 
withdrawn because of its ability to induce agranulocy- 
tosis, but in view of the lack of alternatives has since 
been reintroduced into clinical practice, with the restric- 
tion that its use must be accompanied by rigorous blood 
monitoring.1-3 
Seeman4-6 reported that antipsychotic activity is 
closely correlated with the ability to block D2 dopamine 
receptors but not with D1 receptor blockade, although 
the subsequent development of D1-selective agonists and 
antagonists indicated that D1 receptors may also be 
involved in the clinical response to antipsychoti~s.~-~ For 
10 years or more, the two subtype classification could 
accommodate most of the activities attributed to the 
dopaminergic system. However, this has changed and 
the dopamine receptors have been reviewed recently.lOJ1 
Molecular cloning techniques have permitted the iden- 
tification of several dopamine receptors called D1, D2 
( D ~ L  and Dzs), D3, D4, and D ~ / D ~ B ,  recently grouped 
together into two subfamilies: D1-like ( D ~ A  and D&B) 
and D2-like (D2, D3 and D4) subfamilies. 
The D1-like receptors exhibit very similar ligand 
binding properties: high affinity for benzazepines (SCH 
23390, SKF 38393) and low affinity for butyrophenones 
(spiperone, haloperidol) and substituted benzamides 
(sulpiride). An interesting difference between the D1- 
like receptors is that the D ~ / D ~ B  receptor binds dopam- 
ine with a higher affinity than does the D ~ A  receptor. 
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All three D2-like receptors possess high affinity for 
butyrophenones such as spiperone and haloperidol and 
low affinity for benzazepines such as SKF 38393. The 
D4 receptor exhibits relatively high affinity for the 
atypical neuroleptic clozapine; this has led to specula- 
tion that the D4 receptor might be the relevant target 
of this atypical neuroleptic (for a review of DA receptors, 
see ref 12 and 13). 
Clozapine blocks not only dopamine receptors but also 
5-HTu serotonin receptors, and recent findings suggest 
that its atypical activity may be due to  this latter 
feature.14 This hypothesis is supported by clinical 
evidence that the 5-HTu-blocking capacity of certain 
antipsychotics reduces extrapyramidal side effects and 
improves the outcome of negative symptoms. An ex- 
ample is setoperone, a drug with potent 5-HTu-blocking 
and moderate D2-blocking activity which has proved 
effective in the treatment of negative symptoms in 
schizophrenics and also causes few extrapyramidal 
effects. l5 
In previous papers16J7 we have reported the synthesis 
and antidopaminergic and antiserotoninergic activities 
of 34 aminomethy1)tetralones 1-3, which are conforma- 
tionally restricted butyrophenone structures analogous 
to haloperidol, 4. As a continuation of that work we 
have now prepared the 2-(2-aminoethyl)benzocycloal- 
kanones 20-23, which also possess the essential re- 
quirements for interaction with DA and serotonin (5- 
HT) receptors. These compounds have two butyro- 
phenone pharmacophores, the (aminoethy1)cycloal- 
kanone moiety and the 4-(p-fluorobenzoyl)piperidine 
fragment. This latter, which has been described as a 
neuroleptic pharmacophore of similar potency to the 
butyrophenone portion,18 is also an important feature 
for 5-HTu binding.lg 
On the other hand, it is known that ketanserin 5 is 
the prototypic 5-HTu receptor antagonist. In the 
ketanserin molecule is necessary to consider two struc- 
tural aspects: (a) the quinazolinone moiety is not 
essential and may be replaced by a pyrimido pyrimidine 
(e.g., pirenperone 6) or a thienopyrimidine nucleus (e.g., 
setoperone 7 )  or abbreviated to a simpler structural 
aroyl ketone or amide and (b) there is an aromatic 
binding site that accommodates the aryl portion of the 
heterocyclic ring.lg It is evident that the design of 
molecules under study satisfy these requirements be- 
cause they have an aroyl portion that binds the p -  
fluorobenzoyl fragment across an aminoethyl side chain 
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Figure 2. 
partially incorporated in a conformationally restricted 
cycloalkanone structure. 
Chemistry 
Compounds 20-23 were synthesized via the sequence 
of reactions outlined in Scheme 1. Literature proce- 
dures for the preparation of tetralone- and indanone- 
acetic acids involve condensation with glyoxylic acid in 
alkaline medium and subsequent reduction with zinc 
and acetic acid of the resulting alkene acid.20i21 Other 
synthetic routes have been described for preparing these 
compounds.22-26 
In this paper, indanone, 5-fluoroindanone, tetralone, 
and benzosuberone-2-acetic acids 12- 16 were prepared 
by one of the following methods: (A) aldol condensation 
with glyoxylic acid in alkaline medium to give l-oxo- 
2,3-dihydro-indanylidene acetic acid 8 and their 5-flUOrO 
derivative 9, (l-oxo-l,2,3,4-tetrahydro-2-naphthylidene)- 
acetic acid 10, and (l-oxo-1,2,3,4-tetrahydr0-5H-2-ben- 
zocyclohepteny1idene)acetic acid 11 in variable yields 
and (B) thermal condensation with glyoxylic acid at 160 
"C in quantitative yields (Table 1). Subsequent reduc- 
tion of the alkene acids with zinc and acetic acid gave 
the saturated acids 12-16 also in quantitative yields 
(Table 2). l-lktralone-2-acetic acid, 12, was also pre- 
pared with an overall yield of 75% by hydrolysis of the 
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Table 3. Physical Properties for Compounds 16-19 
n 
R 
yield, recrystn 
compd n R method % mp, "C solv formula 
8 1 H  A 22 
B 57 
201-202 EtOH C11H903 
9 1 F B 69 210-212 EtOH C~~HBOBF 
~~ . . 
10 2 H 6 74" 
188-19ob EtOH C12HlOO3 
B 95 
11 3 H B 70 229-231' EtOH C13H1103 
h reported in ref 20, 67%. mp 184.5-185.5 0C.20 mp 232 
"C (AcOH).~~ 
Table 2. Physical Properties for Compounds 12-15 
Cool I 
R 
compd n R yield, % mp, "C recrystnsolv formula 
12 1 H 66 147-149 AcOEt CllH1003 
14 2 H 95 107-109' AcOEt C12H1203 
15 3 H 87 123-127 AcOEt C13H1403 
13 1 F 92 130-133 toluene CllHgOsF 
Lit.21 144-146 "C; lit." 147-148 "C; lit.26 147-149 "C. Lit.23 
106-108 "C; lit.2S 104-105 "C; lit.37 108 "C; lit.38 107-109 "C. 
corresponding ethyl ester, in turn obtained by alkylation 
of tetralone with ethyl bromoacetate in the presence of 
lithium diisopropylamide. The synthesis of amides 16- 
19 (Table 3) was accomplished in good to excellent yields 
compd n R method 
A 
B 
A 
B 
A 
B 
A 
B 
16 1 H 
17 1 F 
18 2 H 
19 3 H 
yield, recrystn 
% mp, "C solv formula 
85 
Oil" 
80 
75 
72 
85 
81 
90 
78 
127-128 i-PrOH CzsHziNOsFz 
oilb Cz4Hz4NOsF 
117-118 AcOEt C26HzsN03F 
a Bis(2,4-dinitrophenyl)hydrazone, mp 180-181 "C (MeOH). 
Anal. ( C ~ S H ~ O N ~ O ~ F )  C, H, N. MS (FAB) M + 1: 740. Bis(2,4- 
dinitrophenyl)hydrazone, mp 207-208 "C (AcOEt). Anal. 
(C36H32NgOgF) C, H, N. MS (FAB) M + 1: 754. 
by reaction of the acid chlorides with P(p-fluorobenzoy1)- 
piperidine (route A) or by direct acid amine coupling 
with carboxylate activation by dicyclohexylcarbodde 
in the presence of 1-hydroxybenzotriazole (HOBt) (route 
B). Ketalization of both the carbonyl groups with 
ethylene glycol and p-TsOH in toluene gave the bis- 
(ethylene ketals) with variable yields. Later, lithium 
aluminum hydride reduction and subsequent deketal- 
ization then afforded to the amino ketones 20-23 in 
good to excellents yields (Table 4). 
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Table 4. Physical Properties for Compounds 20-23 
n 
compd 
(code number) n R yield, % mp, "C recrystn solv formula 
20 1 H 91 264-266 MeOH Cz3Hz4NOzF.HCl 
(QF 0307B) 
21 1 F 55 270-272 MeOH-Et20 Cz3H23NOzFz'HCl 
(QF 0313B) 
22 2 H 85 176-179 MeOH C24HzeNOzF.HCl 
(QF 0303B) 
23 3 H 80 224.5-226 MeOH-Et20 Cz5H~sNOzF.HCl 
(QF 0311B) 
Table 5a 
pKi values pKi ratios 
drug Di Dz ~ - H T ~ A  Dim2 ~ - H T ~ A / D ~  5-HTU/Dz ~ - H T ~ A  
- haloperidol 7.01 8.30 7.70 0.85 1.10 0.93 
20 5.55 7.15 8.60 0.78 1.55 1.20 8.12 f 0.4 
8.12 f 0.7 21 5.96 7.32 8.42 0.81 1.41 1.15 
22 5.81 7.32 8.11 0.79 1.40 1.11 7.45 It 0.2 
23 5.89 7.33 7.89 0.80 1.34 1.08 6.75 f 0.1 
- 8.87 f 0.1 ketanserin - - - - - 
methysergide - - - - - - 8.84 
(I pK<s were obtained from the inhibition of [3Hlketanserin binding to rat frontal cortex membranes (5-HTza) and [3Hlspiperone or 
L3H1SCH 23390 binding to striatal membranes (D2 or D1) by new compounds. Results are means f SEM of three or four separate 
experiments. D1/Dz, pKi value of D1 binding/Dz binding; ~ - H T ~ A / D ~ ,  pKi value of ~ - H T ~ A  binding/D1 binding; ~-HT~A/&, pKi value of 
5-HTu bindingml binding. pA2 values were obtained against serotonin-induced contractions in rat aorta rings. (-) not evaluated. 
Results and Discussion 
Pharmacology. Dopamine and ~ - H T ~ A  antagonist 
activity of the compounds was evaluated by in vivo and 
in vitro experiments. 
In Vitro Results. In [3Hlspiperone binding assays, 
all the new compounds exhibited pKi values of 7.15- 
7.33, slightly lower than that of haloperidol, 8.3 (Table 
5). In [3H]SCH 23390 binding assays, the new molecules 
again had very similar PKi values (5.55-5.96) which 
were again lower than that of haloperidol (7.01). These 
results indicate that the new compounds are more D2- 
selective than haloperidol. 
In [3H]ketanserin binding experiments, the new mol- 
ecules showed greater affinity for 5-HTu receptors (PKi 
7.89-8.60) than haloperidol (pKi 7.70). The new com- 
pounds exhibited p A p  values of 6.75-8.12,27 slightly 
lower than that of ketanserin (8.87) in suppressing 
serotonin-induced contractions in rat aorta rings stripped 
of endothelium (Table 5). 
pKis for Dz binding (and to a lesser extent pK{s for 
D1 binding) tend to be greater among typical (classical) 
than atypical antipsychotics, whereas these two classes 
of antipsychotic exhibit no difference as regards pK{s 
for ~ - H T ~ A  binding.28,29 
In Vivo Results. All the substances tested caused 
statistical significant reductions in spontaneous motor 
activity (SMA) at a dose of 2 mgkg (Figure 3). Halo- 
peridol and compounds 20, 23, and 21 were effective 
immediately after their administration, and 22,40 min 
later. 
Depending on the reductions of SMA obtained with 2 
mgkg doses, the substances were next assayed at doses 
4 times greater or smaller. The percent reduction in 
SMA measured 60 min after administration of 8 mgkg 
4" 
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Figure 3. Spontaneous locomotor activity in mice treated with 
vehicle (01, haloperidol (0),20 (O), 21 (v), 22 (a), or 23 (A) at 
a dose of 2 mgkg. The data shown are means f SEM 
(accumulated data). Significant differences with respect to 
control indicated by *p < 0.05 or **p '0.01. (1) All values 
showed significant differences with respect to  control (p < 
0.01). Numerical values at the end of each curve show percent 
reduction in SMA 60 min after administration of the drugs. 
of compound 20 or  0.5 mgkg of 23 or 21 was in all three 
cases very similar to that caused by 0.5 mgkg of 
haloperidol, and 22 (8 mgkg) was slightly less active 
(Figure 4). 
The new compounds were also tested for activity 
against amphetamine-induced hyperactivity at doses 
which had caused at least 75% inhibition of SMA 60 min 
after their administration. Haloperidol (ED50 = 0.098 
mgkg ip) or compound 21 at dosages of 0.5 mgkg, 23 
at 0.5 or 2 mgkg, and 20 or 22 at  8 mgkg all inhibited 
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Figure 4. Spontaneous locomotor activity in mice treated with 
haloperidol (O), 21 (v), or 23 (A) at a dose of 0.5 mgkg, or 20 
(+) or 22 (a) at a dose of 8 mgkg. The data shown are means 
f SEM (accumulated data). All values showed significant 
differences with respect to  control 0, < 0.01). Numerical 
values at the end of each curve show percent reduction in SMA 
60 min after administration of the drugs. 
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Figure 5. Antagonism of d-amphetamine-induced hypermo- 
tility in mice treated with vehicle (01, haloperidol (01, or 21 
(v) at a dose of 0.5 mgkg, 23 at doses of 0.5 (A) or 2 mgkg 
(A), or 20 (e) or 22 (a) at a dose of 8 mgkg. All values are 
means f SEM (1) Significant differences 0, < 0.01) with 
respect to control throughout the experiment. Numerical 
values at the end of each curve show the percent reduction in 
hyperactivity 60 min after administration of the drugs. 
amphetamine-induced hyperactivity throughout the 
experiment (Figure 5). 
Apomorphine-induced climbing was strongly inhibited 
by haloperidol (ED50 = 0.15 mgkg ip) and by all the 
new compounds at the highest dose used (Figure 6). If 
it is assumed, following Ferris et al.,30 that climbing is 
caused by activation of limbic dopamine receptors, and 
since antipsychotic activity is the result of blockade of 
DA receptors in the limbic system, then these results 
suggest that the compounds tested can be classified as 
antipsychotics. 
The potency of the compounds under study to inhibit 
spontaneous locomotor activity, amphetamine-induced 
hyperactivity, and apomorphine induced climbing (at the 
highest dose used) was similar. Thus, the indanone 
derivative 21 was the most potent in reducing all 
behaviors, followed by the benzosuberone 23, being the 
least potent 20, analogue of 21, but lacking a fluorine 
atom in position 5, and 22, bearing a tetralone moiety. 
Differences in the affinity for either D1 or D2 receptors 
cannot account for the relative potencies of the com- 
pounds, since their K{s were almost identical. It ap- 
pears that the existence of two complete butyrophenone 
groups, such as in 21, is necessary to show a similar 
profile to haloperidol in behavioral tests. 
Certain experimental results suggest that D2 selectiv- 
ity may be a sign that a drug will induce catalepsy in 
experimental animals (and hence that it may cause 
extrapyramidal symptoms in human  being^).^^^^^ Since 
our binding results showed that all the new substances 
are more D2 selective than haloperidol, we hypothesized 
that they would be more cataleptogenic than haloperidol 
in vivo. Somewhat to our surprise, this was not so. 
Whereas haloperidol, as expected, was markedly cata- 
leptogenic (ED50 = 0.67 mgkg ip, confidence limits 0.5- 
0.9) and induced an average increase in position reten- 
tion time of 28.8 s @ < 0.01) when the larger dose was 
used, the new compounds, in general, exhibited a much 
lower propensity to produce catalepsy. Compounds 20 
and 22 produced, at dosages of 2-8 mgkg, a slight 
increase (no more than 5 s) in the time for which the 
imposed position was maintained and induced no cata- 
lepsy, while the molecules 21 and 23 (dosages of 0.5-8 
mgkg) increased the time in initial imposed posture (in 
the range 10-20 s) and catalepsy was induced in only 
13.3-33.3% and 6.7-16.7% of the tested animals, 
respectively; however, these percentages are much lower 
than those obtained with haloperidol (Figure 7). Fur- 
thermore, the effects of 21 and 23 in the catalepsy test 
differed qualitatively from those of haloperidol: whereas 
animals treated with the new molecules showed reduced 
muscle tone (appeared flaccid), the animals treated with 
haloperidol appeared rigid with high level of muscle 
tone. 
Bruhwyler et al.33 suggested that the induction of 
extrapyramidal symptoms by neuroleptics may be due 
to an imbalance between their effects on dopaminergic 
and cholinergic systems, and that atypical antipsycho- 
tics, such as clozapine, may lack extrapyramidal effects 
because they have both antidopaminergic and anticho- 
linergic activity. To determine whether the weak cata- 
leptogenic activity exhibited by our new compounds 
might be due to anticholinergic activity, we evaluated 
the protection they afforded against eserine (physostig- 
minebinduced lethality. Since none of the new com- 
pounds afforded such protection, even at the highest 
dose used (results not shown), their weak cataleptogenic 
activity cannot, in fact, be attributed to concomitant 
anticholinergic activity. 
Recent studies have suggested that 5-HT2~-blocking 
activity can reduce the cataleptogenic activity of neu- 
roleptics while enhancing their antipsychotic activ- 
ity.3,15,3* Setoperone and ritanserin, for example, both 
of which are more active as ~ - H T ~ A  blockers than as D2 
blockers, have been reported to be more effective than 
selective DA receptors blockers in reducing the negative 
symptoms of schizophrenia and induce few extrapyra- 
midal side effects. In view of such reports, other 
compounds with both 5-HTu-blocking and D2-blocking 
activity have also been developed.35 
According to the binding studies the new compounds 
interacted with both D1 and D2 receptors like haloperi- 
dol, although they had less affinity. However, they were 
slightly more D2 selective compared to haloperidol, as 
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Figure 6. Climbing behavior induced by administration of apomorphine (2 mgkg sc) 30 min after administration of vehicle, 
haloperidol, 20, 21, 22, or 23. All values show means f SEM of the scores obtained between 20-30 min postapormorphine 
administration. Significant differences with respect to control indicated by *p < 0.05 or **p < 0.01. 
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Figure 7. Results of catalepsy test, showing the time for 
which initial posture was maintained (mean f SEM) by mice 
treated with vehicle, haloperidol, 20, 21, 22, or 23. Times in 
excess of 30 s were recorded as 30 s. Significant differences 
with respect to control indicated by *p < 0.05 or **p < 0.01. 
Numerical values at column heads represent the percentage 
of cataleptics. 
shown by the D1/D2 ratio. In contrast, all the new 
molecules displayed higher affinity for 5-HTu receptors 
than haloperidol. Interestingly, in this case the relative 
affinity for serotonin receptors appears to be related to 
the chemical structure of the compounds. 21 and 20, 
both bearing an indanone moiety, but the latter lacking 
the fluorine atom, showed the highest affinity for 
5-HTu; the compound having a tetralone fragment (22) 
exhibited an affinity slightly lower, while 23 with the 
least affinity bore a benzosuberone. In summary, 
increasing the size of the ring which bears the carbonyl 
group diminishes the affinity for serotonin receptors. 
In keeping with the above hypotheses regarding the 
combination of 5-HTu-blocking and D2-blocking activi- 
ties, Meltzer et al.28,29 suggested that atypical antipsy- 
chotic drugs might be characterized by having a pK, 
~ - H T ~ A / D ~  ratio no smaller than 1.12. The pKi 5-HTd 
D1 and pKi ~ - H T ~ A / D ~  ratios of our new compounds were 
all greater than those of haloperidol; only 20 (hereafter 
designed as QF 0307B) and 21 (QF 0313B) have PKi 
~ - H T ~ A / D ~  ratios strictly higher than 1.12, while 22 
XI Xt X3 
p"+ 
V BUTYYOPHENONE PHARMACOPHORE 
Figure 8. Molecular fragments considered in the molecular 
modeling analysis. 
(QF 0303B) may be considered as a borderline case 
(Table 5) .  Our results with QF 0303B, QF 0307B, and 
QF 0311B are in accordance with Meltzer et al. In 
addition, QF 0313B having an appropriate pKi 5-HTd 
D2 ratio induced weak catalepsy in a small percentage 
of animals. 
In summary, these new synthetic molecules had 
pharmacological properties compatible with a profile of 
atypical antipsychotics. 
Molecular Modeling. Structures of the compounds 
(20, 22, 23) were represented as X-Y (Figure 8) where 
Xs are the fused cyclic moieties (indanone, tetralone, 
and benzosuberone; XI, X2 and & in Figure 8) and Y is 
the 4-(pfluorobenzoyl)piperidine fragment common to 
all the compounds. 
Structural fittings of X and Y fragments and the 
butyrophenone pharmacophore of haloperidol were per- 
formed by starting from their most stable conformations, 
superimposing the carbonyl groups, effecting torsions 
bringing the terminal nitrogen as close as possible to 
this of the template molecule, and then optimizing with 
these contraints. All the torsions affected only linear 
aliphatic chains and involved very little change in 
energy. 
Fitting the butyrophenone pharmacophore of halo- 
peridol to Y as above resulted in almost perfect overlap, 
with N atoms at only 0.09 A (Figure 9). Since both 
structures block dopamine receptors (see Pharmacology 
section), this suggests that the active conformation of 
haloperidol fragment may not be its minimum-energy 
conformation (Figure 9a) but a more twisted for closer 
to Y (Figure 9b). In this specific case, the energetic cost 
to acquire this final conformation is only 0.85 kcallmol; 
that it to say, nearly a free rotation. 
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Figure 9. Structural fitting of the haloperidol pharmacophore 
on the 4-(p-fluorobenzoyl)piperidine fragment (Y). (a) Both 
molecules in minimum-energy conformation. (b) Haloperidol 
pharmacophore twisted to match fragment Y. 
Following the same previously described procedure, 
the rigid 4-(pfluorobenzoyl)piperidine fragment (Y) was 
used as a template to which the three X fragments were 
fitted (Figure lo). Since the goodness of the fit was 
unaffected by the size of the rings, and since all the X 
fragments appear to be pharmacologically effective, 
planarity of the aryl systems related to their size seems 
not to influence the dopamine-blocking activity of these 
structures. This finding contrasts with those of a 
parallel study of their 5-HT2~-blocking activity.27 
Experiment a1 Sect ion 
Chemistry. Melting points were determined with a Kofler 
hot-stage instrument or a Gallenkamp capillary melting points 
and are uncorrected. Infrared spectra were recorded with a 
Perkin-Elmer 1600 FTIR spectrophotometer; main bands are 
given in cm-l. Proton magnetic resonance spectra were 
obtained with a Brucker WM-250 (250 MHz) with tetrameth- 
ylsilane as an  internal standard. Mass spectra (FIB) were 
performed with a Kratos MS-50 mass spectrometer using 
2-hydroxyethyl disulfide as a matrix. Elemental analyses were 
performed in a Perkin-Elmer 240B apparatus at the Mi- 
croanalyses Service of the University of Santiago de Compos- 
tela (Spain); all reported values are within f0.4% of the 
theoretical compositions. 
The general method of synthesis described are illustrative 
of those analogous compounds. 
The progress of the reactions was monitored by the thin- 
layer chromatography. 
1-0xo-1,2,3,4-tetrahydro-2-naphthylideneacetic A id 
(10) (Table 1). Method B. A stirred mixture of 2.2 g (15 
mmol) of a-tetralone and 1.48 g (16 mmol) of glyoxylic acid 
 
I 
I 
I 
(C) 
C-C C-C -F -l\i ' 3  
Figure 10. Structural fitting of X fragments on the 4-(p- 
fluorobenzoy1)piperidine fragment (Y) taken as template. (a) 
Indanone (XI); (b) tetralone (X2); and (c) benzosuberone (&I. 
monohydrate was heated in a Dean-Stark apparatus at 160 
"C for 40-45 min. After cooling, the solid which formed was 
thoroughly triturated with ethyl acetate (2 x 50 mL). After 
filtration to separate undissolved materials, the liquid filtrate 
was washed several times with water and dried (Na2S04), and 
the solvent was evaporated to give 2.90 g (95%) of 10. A 
sample for analysis was obtained by recrystallization from 
EtOH. Mp: 188-190 "C. IR (KBr): 3400-2500 (OH), 1700 
(COOH), 1670 (CO), 1640-1600 (C=C). 'H NMR (CDCl3): 6 
8.11-8.08 (d, lH,  H-8), 7.63-7.57 (dt, lH,  H-6), 7.44-7.38 (t, 
lH,  H-7), 7.35-7.31 (d, lH,  H-5) 6.92 (s, lH,  =CHCOO), 3.48- 
3.42 (m, 2H, PhCHZ), 3.17-3.00 (m, 2H, PhCH2CH2). 
1-Oxo- 1,2,3,4-tetrahydro-2-naphthaleneacetic A id (14) 
(Table 2). 14 was prepared by reduction of 10 with zinc dust 
and acetic acid as previously described.38 Mp: 107-109 "C. 
The acetic acid 14 was also prepared by hydrolysis of the 
corresponding ethyl ester as indicated below. 
A solution of 1.06 mL (7.5 mmol) of diisopropylamine in 40 
mL of dried THF was cooled to -20 "C under N2 with stirring. 
n-Butyllithium (3.06 mL of a 2.5 M solution in n-CsH14; 7.5 
mmol) was added, and stirring was continued for 0.5 h between 
-20 and -10 "C. The solution was then cooled to -70 "C and 
stirred 1 h more. A solution of 1.10 g (7.5 mmol) of a-tetralone 
in 8 mL of THF was added dropwise over 5-10 min. After 15 
min at -70 "C the cooling bath was removed and the reaction 
mixture was allowed to warm to room temperature under N2 
over 18 h. The THF was evaporated off, and the residue was 
dissolved in AcOEt/H2O. The solution was washed with 5% 
NaHC03 and 5% HC1 and dried (NazS04), and the AcOEt was 
evaporated off to give 1.71 g of crude product, which was 
purified by chromatography on silica gel with CH2C12 as eluent, 
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yielding 1.34 g (77%) of the desired l-ox0-1,2,3,4-tetrahydro- 
2-naphthaleneacetic acid, ethyl ester. Mp: 47-49 "C. IR 
(KBr): 1730 (COO), 1682 (CO), 1600 (C=C). 'H-NMR 
7.33-7.23 (m, 2H, H-5, H-7), 4.23-4.12 (m, 2H, COOCHZCH~), 
3.20-2.92 (cm, 4H, C H a ,  CH&OO), 2.47-2.35 (m, lH,  2H, 
H-5, H-7, =CHI, 2.30-1.88 (m, 2H, HCHCH=), 1.31-1.22 (dt, 
Acid hydrolysis of this ethyl ester with concentrated HCl 
gave 14 in quantitative yield. Mp: 107-109 "C (EtOH). IR 
(Kl3r): 3100-2500 (OH), 1710 (COOH), 1680 (CO) (see Table 
2). 
l-Oxo-l,2,3,4-tetrahydro-2-naphthaleneacetic Acid 
Chloride. A solution of 76.2 g (0.6 mol) of oxalyl chloride in 
40 mL of anhydrous toluene was added dropwise to  a stirred 
solution of 12.02 g (0.06 mmol) of 13 in 260 mL of anhydrous 
toluene under an atmosphere. The resulting reaction mixture 
was allowed to stir overnight a t  room temperature. The 
solvent was removed under reduced pressure, and the orange 
solid residue was used in the next step without further 
purification. IR: strong band at 1794 cm-l (O=CCl). Quan- 
titative yield. 
N-[(l-Oxo-1,2,3,4-tetrahydro-2-naphthyl)acetyl]-4-@- 
fluorobenzoy1)piperidine (18). Routek A solution of 1.91 
g (22 mmol) of (p-fluorobenzoy1)piperidine in 30 mL of anhy- 
drous toluene was slowly added to a stirred solution of 1.97 g 
(8.9 mmol) of acid chloride in 130 mL of anhydrous toluene 
under argon atmosphere. The resutling mixture was allowed 
to stir for 1 h and then heated under reflux for 24 h. After 
cooling, the solvent was removed under reduced pressure to 
give a brown oil which was dissolved in dichloromethane, the 
resulting solution washed with 10% NazC03 and HzO and 
dried (NaZSOd), and the solvent was removed in vacuo. The 
resulting orange oil was purifed by flash chromatography 
(silica gel, AcOEthexane, 1:l) to give 1.1 g (95%) of a yellow 
oil that does not crystallize on standing. Attempted Kugelrohr 
distillation caused decomposition. IR (film): 1715 (CO cy- 
cloalkanone), 1678 (CO benzoyl), 1643 (CO-N). The bis(2,4- 
dinitropheny1)hydrazone melted at 207-208 "C (AcOEt) (see 
Table 3). 
Route B. Under an argon atmosphere, a solution of 0.61 g 
(2.94 mmol) of 4-(p-fluorobenzoyl)piperidine, N-hydroxyben- 
zotriazole (0.80 g, 5.88 mmol), and 0.60 g (2.94 mmol) of the 
acid 14 was stirred at room temperature for 1 h; 1.21 g (5.88 
mmol) of NJV-dicyclohexylcarbodiimide was then added to the 
cooled mixture (0 "C) which was stirred at 0 "C for 1 h and 
then for 16 h at room temperature. After removal of the DMF 
in vacuo, the residue obtained was dissolved in CHzClz (150 
mL), and the resulting solution was washed with 5% NaHC03 
(2 x 25 mL) and HzO (2 x 40 mL) and dried (NaZSOd), and 
the solvent was removed under reduced pressure. The oil 
residue was purified by flash chromatography (silica gel, 
AcOEthexane 1:l) to give 0.94 g (81%) of a yellow oil that was 
identified by IR and as 2,4-dinitrophenylhydrazone, mp 207- 
208 "C (EtOH) (see Table 3). 
N-[B-( l-Oxo-1,2,3,4-tetrahydro-2-naphthyl)ethyl]-4-(p- 
fluorobenzoy1)piperidine Bis(ethy1ene ketal). A stirred 
solution of 1.76 g (46 mmol) of the amide 18, 17.27 g (0.28 
mmol) of ethylene glycol, and 54 mg of p-TsOH in 55 mL of 
anhydrous toluene was refluxed in a Dean-Stark apparatus 
for 22.5 h with azeotropic distillation of water. After cooling, 
the toluene solution was washed with 10% NazC03 (2 x 30 
mL) and HzO (2 x 30 mL) and dried (Na2S04), and the solvent 
was removed under reduced pressure. The resulting crude bis- 
ketal (2.05 g, 95%) was an  orange oil with only one 1R band 
(1650, CO-N) and was used in the next step without further 
purification. 
N-[B-(1-0xo-1,2,3,4-tetrahydro-2-naphthyl)ethyll-4-@- 
fluorobenzoy1)piperidine (22). A solution of 0.83 g (0.003 
mol) of 18 bidethylene ketal) in 25 mL of ether was added 
dropwise to a stirred suspension of 0.47 g (0.012 mol) of LiAlH4 
in 16 mL of anhydrous ether under an argon atmosphere. The 
reaction mixture was heated under reflux for 8 h, cooled a t  0 
"C in an ice bath, and quenched by the sequential dropwise 
addition of HzO (0.5 mL), 10% NaOH (0.7 mL), and HzO (3 
mL). The coarse precipitate formed was filtered off and 
(CDCl3): 6 8.04-8.01 (dd, lH,  H-81, 7.50-7.44 (dt, lH,  H-6), 
3H, CH3). 
thoroughly washed with ether. The combined filtrates were 
treated with 10% HC1 and stirred vigorously at  35-40 "C for 
1 h. On cooling, the aqueous layer was made alkaline with 
10% NaOH and extracted with ether (3 x 50 mL), the 
combined ether extracts were dried (NazSOJ, and the solvent 
was partially removed under reduced pressure. 'Ib the result- 
ing concentrated solution was cautiously added ether-satu- 
rated HC1 gas. The white precipitate that formed was 
recovered and kept overnight in a vacuum desiccator; recrys- 
tallization from MeOH afforded 0.61 g (85%) of white crystals. 
Mp: 279-281 "C. Spectral data for the free base follows. IR 
(film): 1710 (CO cycloalkanone), 1678 (CO benzoyl). 'H-NMR 
(CDCl3): 6 8.04-7.93 (m, lH,  H-8), 7.49-7 42 (dt, lH,  H-6), 
7.337.21 (m, 2H, H-5, H-7), 7.16-7.09 (dd, 2Ho-Ph-F), 3.06- 
2.98 (m, 4H, CHzCHzN), 2.62-1.62 (complex multiplet). Anal. 
Pharmacology. Drugs and Chemicals. All compounds 
were administered in 0.01 m u g  injections (apomorphine 
subcutaneously and all others intraperitoneally). Compound 
20 was administered as a suspension in 0.5% (w/v) sodium 
carboxymethylcellulose (Merck); haloperidol (Sigma) and com- 
pounds 21 and 23 were dissolved in 1% lactic acid in water; 
dextroamphetamine sulfate (Sigma), atropine hydrochloride 
(Sigma), eserine (physostigmine) hemisulphate (Sigma), and 
compound 22 were prepared in saline; and apomorphine 
hydrochloride (Sigma) was dissolved in 0.9% saline solution 
with 1% ascorbic acid (w/v) to prevent oxidation. Chemicals 
used for physiological solutions were of analytical grade. 
Experimental Animals and Conditions. Male Charles 
River CD1 albino mice weighing 25 f 2 g, male Wistar rats 
(275 f 25 g), and male Sprague-Dawley rats (275 f 25 g) 
were used. "In vivo" assays was carried out in a quiet room 
thermostated at 22 f 1 "C with a 12-h lighudark cycle (08.00- 
20.00) and always at  the same time of day (so as to avoid 
variation due to circadian rhythms). Food and tap water were 
free available in the home cage. 
"In Vivo" Experiments. Locomotor Activity. Spontane- 
ous locomotor activity was monitored in six groups of five mice 
during 1 h following administration of haloperidol, 21, or 23 
a t  doses of 0.5 or 2.0 mgkg, 20 or 22 at doses of 2 or 8 mgkg, 
or vehicle alone. In experiments to  determine amphetamine- 
induced hyperactivity, 5 mgkg of dextroamphetamine sulfate 
was administered to 4-10 groups of three mice 30 min after 
administration of vehicle, haloperidol (0.063, 0.094, 0.125, or 
0.5 mgkg), compound 23 at doses of 0.5 or 2 mgkg, 21 at a 
dose of 0.5 mgkg, or 20 or 22 at  a dose of 8 mgkg. Both 
spontaneous and amphetamine-induced motor activity were 
recorded during the following hour in an activity cage (Panlab 
Actisystem D.A.S. 16 V.l), which contains an  electromagnetic 
field that is sensitive to any motion within it. 
Catalepsy. This was tested in mice (n = 15-30) 60 min 
after administration of vehicle, haloperidol (0.25, 0.5, 0.8, 1, 
or 2 mgkg), compounds 21 or 23 (0.5, 2 or 8 mgkg), or 20 or 
22 (2 o r  8 mgkg). The mice were placed with their forepaws 
on one horizontal wire and their hindpaws on another 6 cm 
away and 2 cm lower. The time during which the mouse 
maintained this position was recorded, and more than 30 s 
was considered to  indicate catalepsy. 
Eserine (Physostigmine)-Induced Mortality. Groups of 
10 mice (two groups per compound and dosage level) were 
treated, 30 min before eserine injection (2 mgkg), with vehicle, 
atropine (4 mgkg), haloperidol, compounds 21 or 23 (2 mg/ 
kg), or 20 or 22 (8 mgkg). The mice were placed in cages and 
deaths were counted 60 min after injection of eserine. 
Apomorphine-Induced Climbing. The method of Pro- 
was used with a minor modification. The climbing 
behavior of mice was observed in individual cylindrical stain- 
less-steel wire cages (diameter, 12 cm; height, 14 cm). Mice 
(six per compound and dosage, except for the control group, 
for which 12 animals were used) were treated with vehicle, 
haloperidol (0.125-0.25 mgkg), or compounds 20, 21, or 23 
(0.5,2, or 8 mgkg) or compound 22 (2,8, or 16 mgkg), and 30 
min later with 2 mgkg of apomorphine (subcutaneously). 
During the next 30 min, climbing activity was recorded every 
10 min using the following scale: 0, four paws were on the 
floor; 1, one or two paws were against the grid wall; and 2, 
(Cz4H26NOzF.HCl) C, H, N. 
2572 Journal of Medicinal Chemistry, 1994, Vol. 37, No. 16 Fontenla et al. 
the mouse clung to the grid wall with three or four paws. The 
scores recorded 20 and 30 min postapomorphine were added, 
and the mean of this sum was calculated for each group. 
"In Vitro" Experiments. Male Wistar rats were killed by 
cervical dislocation and decapitation. Both striata and the 
frontal cortex were quickly dissected out on a cold plate, 
weighed, and stored at -20 "C until assay. 
Dz Binding. For [3H]spiperone binding assays, paired 
striata were homogenized in 50 volumes of ice-cold 50 mM Tris- 
HCl with a Polytron (setting 6 for 5 s) and then centrifuged 
at 40000g for 10 min in a Sorvall centrifuge at 4 "C. The pellet 
was resuspended and the process repeated. The final pellet 
was resuspended in 200 volumes of 50 mM Tris-HC1 buffer 
containing 120 mM NaC1. Samples (200 yL) of the final 
suspension were incubated for 10 min at 37 "C with 25 pL of 
displacing agent or its vehicle (10% methanol) and 25 pL of a 
solution of [3H]spiperone; the reaction was terminated by rapid 
vacuum filtration through Watman GF/C filters, which were 
washed with 3 x 5 mL of cold buffer. For equilibrium 
saturation analysis, six ligand concentrations from 0.05-1 nM 
were used. Nonspecific binding was determined by addition 
of M (+)-sulpiride. For determination of the IC50 values 
of drugs displacing [3Hlspiperone (0.25 nM) binding, at least 
six ascending concentrations of each drug were used 
M). Assays were carried out in triplicate at each ligand 
or displacing drug concentration. 
D1 Binding. For [3H]SCH 23390 binding assays, paired 
striata were homogenized in 200 volumes of 50 mM Tris-HC1 
buffer and centrifuged at l O O O g  for 10 min, and the superna- 
tant was centrifuged at  20000g for 10 min. The pellet was 
resuspended and the process repeated. The final pellet was 
resuspended in 50 mM Tris-HC1 containing 120 mM NaC1, 5 
mM KC1, 2 mM CaC12, and 1 mM MgC12. Saturation curves 
were constructed with six ligand concentrations from 0.15 to 
2.5 nM. Nonspecific binding was determined by addition of 
unlabeled SCH 23390 M). Samples were incubated at 
25 "C for 30 min. 
S-HTu Binding. Frontal cortex tissue was homogenized 
(Ultraturrax 5, s at  20 000 rpm) in 50 volumes of 50 mM Tris- 
HCl, pH 7.4, and centrifuged a t  30000g for 10 min at  4 "C. 
The pellet was rehomogenized and centrifuged again. The 
final pellet was reconstituted in 200 volumes of buffer. Ali- 
quots of membrane preparations (200 yL) were incubated with 
25 pL of 1 nM [3H]ketanserin (NEN 60 CUmmol). Specific 
binding was defined by incorporation of 25 yL of methysergide 
(final concentration 1 yM). Samples were incubated for 15 min 
at 37 "C, and incubation was terminated by vacuum filtration. 
Aorta Ring Experiments. Endothelium-stripped aorta 
rings from Sprague-Dawley rats were mounted under a 
resting tension of 1.5 gin a 20-mL organ bath containing Krebs 
solution (composition (mM): NaC1, 118.07; KC1,4; CaC12H20, 
2.5; MgSOs7Hz0, 1.2; KHzPO4, 1.2; NaHC03,25; glucose, 11) 
at 37 "C bubbled with carbogen (95% 0 2 , 5 %  COz). Isometric 
contraction forces were measured using a CPUL 0-25-g 
transducer connected to  a Celaster 10s-1 apparatus. After 
stabilization for 60 min, cumulative concentration-response 
curves were constructed as per Van Rossum,4O increasing 
serotonin concentrations from 30 nM to 10 mM in the absence 
or in the presence of increasing concentrations of ketanserine 
or new compounds. 
Expression of Results and Statistical Analysis. Phar- 
macological calculations were obtained by PCS program (Phar- 
macologic Calculation System).41 The statistical significance 
of differences between means was determined by Student's test 
for unpaired data, the differences with probabilities lower than 
0.05 were considered statistically significant. Percentage 
change in locomotor activity (% LC) was calculated as: % LC 
= [(mean no. of movements by control animals) - (mean no. 
of movements by treated anima1s)jJmean no. of movements 
by control animals) x 100. The percentage of animals showing 
catalepsy (% C) was calculated as (no. of animals showing 
catalepsy)/(total no. of animals) x 100. ED50 values were 
calculated by Litchfield and Wilcoxon's method in the catalepsy 
test. 
Inhibition constant (Ki) values were calculated from the 
Cheng-Prussof equation: K, = IC50/[1 + (F/KD)I, where F is 
the total concentration of 3H-ligand used, KD is the equilibrium 
dissociation constant, and IC50 is the drug concentration 
required to inhibit 50% of specific binding.42 Percentage 
specific binding was calculated as [(dpm sample) - (dpm 
nonspecific binding)Y[(dpm total binding) - (dpm nonspecific 
binding)] x 100. Competitive antagonism was quantified as 
~ A z ,  which was calculated from a Schild plot of log (dose ratio 
- 1) for three antagonist concentrations; six replicate experi- 
ments were performed. 
Molecular Modeling. The geometries of molecular frag- 
ments were optimized by the AM1 method43 as implemented 
in the program MOPAC.44 For both these computations and 
structural fitting, the molecular modeling package BIOSYM 
Inc., San Diego, CA, was used. 
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